GLP1R and metabolic dysfunction-associated steatohepatitis: Tirzepatide, through combined GLP-1 and GIP receptor activity, appears to offer superior efficacy in both NASH resolution and fibrosis regression, underscoring the potential of dual incretin-based therapies in MASLD management.